CT 7510
Alternative Names: CT-7510Latest Information Update: 25 Jan 2022
At a glance
- Originator Carrick Therapeutics
- Class Antineoplastics
- Mechanism of Action Cyclin dependent kinase 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Jan 2022 CT 7510 is available for licensing as of 14 Jan 2022. https://www.carricktherapeutics.com/partnering/
- 07 Oct 2021 Preclinical trials in Cancer in Ireland, prior to Ocotber 2021 (PO)